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Figure 1. Genetic Analysis of BCL10 in Germ
Cell Tumors (GCTs) and B Cell Lymphomas
(A) PCR-SSCP analysis. (a) and (c), GCT; (b)
and (d), lymphoma. (a) and (b), exon 1; (c) and
(d), exon 3.2. Arrows indicate conformational
changes. N, normal; T, tumor; CL, cell line;
tumor numbers are indicated on top.
(B) PCR sequence analysis. (a) and (b),
Tera-1; (c), GCT-44; (d) and (e), Tera-2; (f),
T-243A; (g)±(i), 240A. Panels (a)±(e) show ab-
sence of mutations in GCT cell lines in relation
to Willis et al. (1999) report, where boxes indi-
cate base change and upward arrow indi-
cates insertion positions. Positions in coding
region of cDNA are: (a), 172 bp; (b), 653 bp;
(c), 172 bp; (d), 58 bp; (e), insertion at 499 bp.
Panel (f), A/G heterozygosity at position 2 of
codon 213. Panels (g)±(i) indicate loss of het-
erozygosity at codon 5 (underlined) in tumor
and cell line 240A. Panel (g), normal DNA;
panel (h), tumor DNA; panel (i) cell line DNA.
The residual peak of G in panel (h) indicates
the presence of contaminating normal cells.
(C) Multiplex RT-PCR analysis of BCL10 ex-
pression in GCT. Primers from the 59 coding
region (59-GGACCCGGAAGAAGCGCCATC
TCC-39 and 59-AAGTAGTCTAACAATTTTCCA
GCCC-39) spanning two different exons were
used to amplify a 249 bp PCR product. PCR
was performed utilizing AmpliTaq DNA poly-
merase (PE Applied Biosystems, Foster City,
CA). The 450 bp PCR product represents
b-actin as control. Marker, PhiX HaeIII; tumor
and cell line numbers are shown on top.
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germ cell neoplasms, and colon carcinomas. Thus, the
investigators proposed that alterations of BCL10 may
contribute to the pathogenesis of several types of neo-
plasia.
The observation of most interest to us was that BCL10,
which maps to chromosome 1p22, exhibited mutations
in all three MM cell lines analyzed. We had previously
shown 1p22 to be a frequent site of allelic loss in MM
(Lee et al., 1996), which implicated the involvement of
a tumor suppressor gene (TSG) at this location. The aim
of this letter is to report the results of our studies of
BCL10 as a candidate for the 1p22 putative TSG in MM,
and to prompt further discussion about the potential
role of this gene in human malignancy.
Fifty MM cell lines were examined for loss of heterozy-
gosity (LOH). Since YAC 929E1 contains BCL10 (Willis
et al., 1999), two microsatellite markers, D1S2766 and
D1S1618, were selected for analysis, as they were deter-
mined through a database search (http://www-genome.
wi.mit.edu) and PCR analysis to map to this YAC. Over-
all, 25 of 45 informative cases (55.6%) showed LOH of
at least one of these two loci, with the higher frequency
of allelic loss being at marker D1S1618 (18 out of 30
Figure 1. SSCP and Sequence Analyses of BCL10 in MM Cell Linesinformative cases, 60%) (data not shown). However, the
SSCP analysis was performed on genomic DNA. The entire codingpercentage of MMs with LOH in the vicinity of BCL10
sequence of BCL10 was amplified with AmpliTaq (Perkin Elmer) andis less than that previously observed for markers within
previously described primers (Willis et al., 1999), using standardthe minimally deleted 1p22 region in this malignancy
PCR conditions. Autoradiographs at left show PCR products gener-(Lee et al., 1996). Furthermore, YAC 929E1 resides distal
ated by primers corresponding to exon 3.2 (A) or exon 1 (B) analyzed
to this minimally deleted segment. on 10% nondenaturing acrylamide gels. Lanes 1±4: MM cell lines,
RT-PCR was performed on MM cell lines that dis- as indicated; lane 5: PBL DNA from a normal individual (PBL). Tem-
plates for sequencing were amplified from genomic DNA by PCRplayed LOH to determine the expression pattern of
with AmpliTaq and primers flanking each exon of BCL10. The chro-BCL10. Normal mesothelial cells and MM cell lines not
matograms at right show sequence differences between Meso 17exhibiting LOH at 1p22 were included as controls. All
and PBL (A) or between Meso 38 and PBL (B). Arrows indicatecell lines examined expressed BCL10 at similar levels
altered nucleotides.
(data not shown). The housekeeping gene GAPDH was
also expressed at uniform levels in all cell lines tested. In
summary, BCL10 was demonstrated to map to a region MM cell lines amplified with exon 3.2 primers displayed
identical banding patterns, which differed from thoseshowing frequent LOH in MM, but expression of BCL10
did not appear to be altered in any of the tumor cell observed in normal PBL samples. Examples of band
shifts are shown in Figure 1. We also carried out SSCPlines examined.
To determine whether the BCL10 gene is mutated in analysis of eight tumor samples matched to MM cell
lines displaying variant bands. In each case, identicalMM, SSCP analysis was performed on genomic DNAs
from 25 MM cell lines displaying LOH in 1p22, using patterns were observed in the tumor and the corre-
sponding MM cell line. Variant bands were not observedprimers described by Willis et al. (1999). Peripheral blood
lymphocyte (PBL) samples from two healthy donors in BCL10 products from exons 2 and 3.1 (262 bp at the
59 end of exon 3).were included as controls. Band shifts were observed
in MM PCR products amplified with primers specific for Reproducible band shifts in DNA from MM cases were
further investigated by direct sequencing of purifiedexons 1 and 3.2 (257 bp at the 39 end of exon 3) of
BCL10. Variant exon 1 bands were demonstrated in 18 PCR products. The sequences derived from the MM
samples were compared with the published BCL10 se-of 25 MM cell lines. However, these band shifts ap-
peared to be identical in 17 of these cell lines and in quence (accession number AJ006288). Nucleotide alter-
ations detected in PCR products from MM samples areone of the normal PBL samples. Products from two
Table 1. DNA Sequence Alteration of BCL10 Detected in MM
Meso DNA Amino Acid Allele
Cell Line Exon Alteration Alteration Frequencya
3, 5, 6, 8, 13, 15 1 24 G→C Lys 8 Lys NDb
17, 23, 25, 28, 33, 36,
38, 42, 43, 44, 52, 59
38 1 13 G→T Ala 5 Ser 3%
17, 59 3 638 G→A Gly 213 Glu 9%
a Percentage shown represents allele frequency in a general population.
b ND, not determined.
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presented in Table 1. Some of these changes were pre- In Response to Fakruddin et al.
dicted to result in substitutions of amino acids at the and Apostolou et al.corresponding positions in the protein sequence. In
each of these cases, individual tumor DNA samples pos-
sessed the same sequence as that of the corresponding
cell line. We agree with many of the above findings, including
To determine if the divergent sequences represented the frequency and nature of BCL10 polymorphisms.
mutations of the BCL10 gene or polymorphisms, a panel However, it appears that some BCL10 abnormalities
of 50 normal genomic DNA samples from the general may be found only in RNA and not genomic DNA, sug-
population was screened (data not shown). The nucleo- gesting that BCL10 may undergo posttranscriptional se-
tide alteration in exon 1 seen in 18 MMs (Table 1) was quence modification.
assumed to be a polymorphism, because it was ob- Wild-type BCL10 is proapoptotic and behaves as a
served in numerous MMs and a control sample, and it tumor suppressor gene (Koseki et al., 1999; Thome et
did not predict an amino acid change. Thus, this variant al., 1999; Willis et al., 1999; Yan et al., 1999; Zhang
was not studied further. The nucleotide change in exon et al., 1999). BCL10 sequence abnormalities were first
1 (nucleotide 13) of Meso 38 destroys an AciI restriction detected in cDNA clones from a MALT lymphoma with
enzyme site. Restriction enzyme analysis revealed that t(1;14) and were unusually heterogeneous. An identical
three of 50 samples from the general population do not spectrum of cDNA abnormalities has been detected in
possess this AciI site, which corresponds to an allele other t(1;14) MALT lymphomas (Zhang et al., 1999), mak-
frequency of 3%. The nucleotide alteration in exon 3 ing it unlikely that all these changes represented RT,
(nucleotide 638) of Meso 17 and Meso 59 does not occur PCR, or cloning artifacts.
at a restriction enzyme site. Therefore, we performed We initially sequenced cDNA clones from 6 malignant
SSCP analysis on these two MMs and 50 normal DNA cell lines, including Tera-1, Tera-2, and GCT-44 and
samples. Nine of 50 DNA samples from normal individu- three mesothelioma lines, and in each, BCL10 abnormal-
als (allele frequency, 9%) displayed banding patterns ities were detected (Table 2 of Willis et al., 1999). Addi-
identical to those observed in Meso 17 and Meso 59 tional cDNA clones from Tera-2, a cell line that exhibits
(Table 1). Thus, we conclude that all of the nucleotide
differences detected in our MM cell lines and tumors Table 1. Summary of Tera-2 BCL10 cDNA Data
represent polymorphisms in the general population. We
Predicteddid not observe any of the nucleotide alterations re-
Homopoly- Splice Proteinported by Willis et al. (1999). Therefore, it would be
Clone Point Mutations meric Varia- (amino
important to determine if any of their alterations are # (codon) Runs tions acids)
polymorphisms.
(A) Normal CloneFinally, we performed sequence analysis on DNA from
1 nil nil nil 233 wild
PBL samples matched to the three cell lines (Mesos 17, type
38, and 59) that exhibited nucleotide changes predicting (B) Clones with Insertions/Deletions within the Homopolymeric
amino acid substitutions. The identical nucleotide se- Runs Alone
2 nil 499 ins TT nil 172quence was observed in DNA from both tumor and nor-
3 nil 499 ins T nil 168mal tissues from the same individual, indicating that
4 nil 136 del Athese base changes are representative of the constitu-
499 ins T nil 68
tional (inherited) genome in each case. In conclusion,
(C) Mutated Clones 1/2 Other AbnormalitiesBCL10 is not mutated or abnormally expressed in MM,
5 N93S AAC→AGC nil nil 233and this gene can be ruled out as a candidate for the
6 N93S AAC→AGC
1p22 TSG in this malignancy. del A codon 149 nil nil 171
7 H40H CAT→CAC silent
K45Q AAA→CAA nil nil 233Sinoula Apostolou,* Assunta De Rienzo,*
8 M153V ATG→GTG
Siva S. Murthy,* Suresh C. Jhanwar,² L177L CTA→CTG silent
and Joseph R. Testa*³ A200A GCT→GCC silent nil nil 233
9 R58Q CGA→CAA*Fox Chase Cancer Center
S218F TCT→TTT nil nil 233Philadelphia, Pennsylvania 19111
10 R58Q CGA→CAA²Memorial Sloan-Kettering Cancer Center
T168T ACT→ACC silentNew York, New York 10021
S218F TCT→TTT nil nil 233
11 H40R CAT→CGT
L41L CTA→CTT silent³ To whom correspondence should be addressed (e-mail: jr_testa@
N217S AAC→AGC 499 ins T nil 168fccc.edu).
12 A20T GCC→ACC
V26V GTA→GTG silent
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